The orally available Btk inhibitor ibrutinib (PCI-32765) protects against osteoclast-mediated bone loss.

Shinohara M, Chang BY, Buggy JJ, Nagai Y, Kodama T, Asahara H, Takayanagi H.Bone. 2014 Mar;60:8-15. doi: 10.1016/j.bone.2013.11.025